drugset / Trial / NCT04166474
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Phase 4
Completed
36 enrolled
Helen Reynolds
Desmond Tutu HIV Centre · collabInfectious Disease Institute, Kampala, Uganda · collab
NaSequentialOpen-labelTreatment
Summary
This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when administered with standard, medium and high dose rifampicin.
Timeline
- Start
- 2021-11-18
- Primary completion
- 2024-02-07
- Completion
- 2024-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |